Liquid chromatography–tandem mass spectrometry (LC–MS/MS) reveals distinct sphingolipid patterns in anorexia and obesity.
|Articles|July 2, 2010
- The Column-07-02-2010
- Volume 6
- Issue 12
Core Values
We spoke to Terrell Mathews from Phenomenex about the rationale behind the development of their Kinetex core-shell particle columns.
Advertisement
Alasdair Matheson spoke to Terrell Mathews from Phenomenex about the rationale behind the development of their Kinetex core-shell particle column and the benefits that they offer chromatographers.
Articles in this issue
over 16 years ago
Capillary chromatography awardsover 16 years ago
Liquorice treats Allsortsover 16 years ago
Shoo flyover 16 years ago
Brazilian informatics solutionover 16 years ago
Global Concerns Drive LC Developmentover 16 years ago
Welcome to Your New Global EditionAdvertisement
Related to this article
Leon Niezen and Gert Desmet discuss uncertainty-driven LC method development, peak overlap, and moving from in silico to real data.
Leon Niezen and Gert Desmet describe how predictive uncertainty can make automated LC method development more reliable.
Liquid chromatography–mass spectrometry (LC–MS) serum profiling ties lysine compounds to lupus kidney disease.
Liquid chromatography-mass spectrometry (LC–MS) growth lifts Waters Q3; MOBILion ion mobility buy expands proteomics.
Liquid chromatography–tandem mass spectrometry (LC–MS/MS) measures galactose-1-phosphate in dried blood spots to monitor galactosemia.
Sam Whitmarsh explores how retention-time models handle interlaboratory data, novel chemotypes, unusual phases and ionisable compounds, and what labs need to do to build useful in-house models.
Advertisement
Advertisement
Trending on LCGC International
1
AI/ML Now: Toxicity Prediction for Unknown LC–HRMS Features Using Machine Learning
2
LCGC Blog: Building a Career Series That Goes Beyond the Surface
3
Industry Roundup: Waters Posts Strong Third Quarter as LC–MS and Chromatography Consumables Drive Growth, Acquires Ion Mobility Pioneer MOBILion
4
From 9000 Clues to a Clinical Test: Mass Spectrometry-Driven Lipidomics for Early Cancer Detection
5